Synthetic epidermal growth factor receptor (EGFR)-mitochondria desired axles-based split green-fluorescent-protein (GFP) could screen for the signaling molecules that overcome the drug resistance to tyrosine kinase inhibitor (TKI) by Chen, Robert & Yu, Wei-hsuan
Research Ideas and Outcomes 2: e9551
doi: 10.3897/rio.2.e9551 
Reviewable  v1
Conference Abstract 
Synthetic epidermal growth factor receptor
(EGFR)-mitochondria desired axles-based split
green-fluorescent-protein (GFP) could screen for
the signaling molecules that overcome the drug
resistance to tyrosine kinase inhibitor (TKI)
Robert Jeenchen Chen , Wei-hsuan Yu
‡ Cardiothoracic Surgery, Taipei Tzuchi Hospital, Tzuchi University College of Medicine, New Taipei City, Taiwan
§ Laboratory  of  Connective Tissue and Stem Cell  Research,  Department  of  Biochemistry  & Molecular  Biology,  National
Taiwan University College of Medicin, Taipei, Taiwan
| Laboratory of Connective Tissue and Stem Cell Research, Department of Biochemistry & Molecular Biology, National Taiwan
University College of Medicine, Taipei, Taiwan
Corresponding author: Robert Jeenchen Chen (rjcc@ntu.edu.tw) 
Received: 14 Jun 2016 | Published: 23 Jun 2016
Citation: Chen R, Yu W (2016) Synthetic epidermal growth factor receptor (EGFR)-mitochondria desired axles-
based split green-ﬂuorescent-protein (GFP) could screen for the signaling molecules that overcome the drug
resistance to tyrosine kinase inhibitor (TKI). Research Ideas and Outcomes 2: e9551. doi: 10.3897/rio.2.e9551 
Abstract
Background
The epidermal growth factor receptor (EGFR) pathway, involving in cancer cell migration,
proliferation,  and  survival,  attracts  lots  of  attention  of  cancer  biologists  for  seeking
therapeutic targets. Tyrosine kinase inhibitor (TKI)-resistance of small cell lung cancer and
cancer stem cells,  the sub-population with EGFR mutations,  has been associated with
frustrating outcomes for anti-EGFR-based therapy.
‡,§ |
© Chen R, Yu W. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY
4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are
credited.
New information
Methods & Results 
With our synthetic EGFR-mutant axles that enlightened mitochondria, the small-cell lung
cancer CL1-0 cell  line interestingly revealed good correlation of  the activated EGFR or
spontaneously activated EGFR mutant T790M/L858R with high energy-demanding status.
The facts  implied that  EGFR signaling might  induce mitochondria  proliferation to  meet
cellular  energy  demand  by  an  unknown  mechanism.  The  activated  EGFR  resulted  in
elevated MMP7 expression and further induced mitochondria proliferation in multiple cell
lines. Therefore, enzymatically dead mutant MMP7 N-GFP fusion protein could be used as
baits to screen for the putative substrates that modulate signals transduction from EGFR to
mitochondria proliferation.
Conclusion 
This synthetic cellular model platform could screen for a variety of mitochondria-targeting
molecules, such as mitochondria ATP synthetase inhibitor, namely compound X, in lung
cancer  cells  in  cooperation  with  Geﬁtinib,  a  widely  used  TKI,  to  see  whether  it  may
increase the  eﬃcacy  of  Geﬁtinib  on  the  resistant  cells  by  cutting  oﬀ  energy  supply  in
mitochondria.
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